PTPRC and hepatocellular carcinoma: applied two different scRNA-seq technologies based on more than 75,000 CD45+ individual immune cells from the tumor, adjacent liver, hepatic lymph node, blood, and ascites of 16 patients with HCC to explore a sufficient resource for understanding/characterizing the immune cells in HCC (117).